Director/PDMR Shareholding

RNS Number : 1306M

ReNeuron Group plc

21 August 2013

 



DTR3

NOTIFICATION OF TRANSACTIONS OF DIRECTORS/ PERSONS DISCHARGING MANAGERIAL RESPONSIBILITY AND CONNECTED PERSONS

All relevant boxes should be completed in block capital letters.

1.	Name of the issuer ReNeuron Group plc	2.	State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.2R; or (ii) a disclosure made in accordance with LR 9.8.6R(1); or (iii) in accordance with section 793 of the Companies Act 2006 (i)
3.	Name of person discharging managerial responsibilities/director Sir Chris Evans	4.	State whether notification relates to a person connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person Director named in 3.
5.	Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a non-beneficial interest 1 Interest of person named in 3	6.	Description of shares (including class), debentures or derivatives or financial instruments relating to shares Ordinary Shares
7.	Name of registered shareholders(s) and, if more than one, the number of shares held by each of them Merlin General Partner II Limited on behalf of Merlin Biosciences Fund II LP and GbR on behalf of Excalibur Malta Ventures Limited on behalf of Hookstone Limited	8.	State the nature of the transaction Disposal of Ordinary Shares by Merlin Biosciences Fund LP and GbR Acquisition of Ordinary Shares by Hookstone Limited Acquisition of Ordinary Shares by Excalibur Malta Ventures Limited
9.	Number of shares, debentures or financial instruments relating to shares acquired Acquisition of 20,000,000 Ordinary Shares by Hookstone Limited, which is controlled by a trust the beneficiaries of which include Sir Chris Evans and certain family members. Acquisition of 4,000,000 Ordinary Shares by Excalibur Malta Ventures Limited, which is controlled by a trust the beneficiaries of which include Sir Chris Evans and certain family members.	10.	Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage) 1.34%
11.	Number of shares, debentures or financial instruments relating to  shares disposed Sir Chris Evans ceased to be indirectly interested in 37,319 Ordinary Shares by reason of his interest in Merlin Biosciences Fund II LP (Merlin Biosciences Fund LP and GbR disposed of 57,600,000 Ordinary Shares in aggregate).	12.	Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage) 0.001%
13.	Price per share or value of transaction 2.5 pence per Ordinary Share	14.	Date and place of transaction 19 August 2013
15.	Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage) Sir Chris Evans is interested in a total of 24,010,525 Ordinary Shares representing approximately 1.3422% of issued Ordinary Shares (being (i) 20,000,000 Ordinary Shares by Hookstone Limited, which is controlled by a trust the beneficiaries of which include Sir Chris Evans and certain family members. Such Ordinary Shares are registered on behalf of Hookstone Limited, (ii) 4,000,000 Ordinary Shares by Excalibur Malta Ventures Limited, which is controlled by a trust the beneficiaries of which include Sir Chris Evans and certain family members. Such Ordinary Shares are registered in the name of Excalibur Malta Ventures Limited ,and (iii) 10,525 Ordinary Shares by reason of his investment in Merlin Biosciences Fund LP and GbR. Such Ordinary Shares are registered in the name of Merlin General Partner II Limited on behalf of Merlin Biosciences Fund II LP and GbR.	16.	Date issuer informed of transaction 19 August 2013

If a person discharging managerial responsibilities has been granted options by the issuer complete the following boxes

17.	Date of grant	18.	Period during which or date on which it can be exercised
19.	Total amount paid (if any) for grant of the option	20.	Description of shares or debentures involved (class and number)
21.	Exercise price (if fixed at time of grant) or indication that price is to be fixed at the time of exercise	22.	Total number of shares or debentures over which options held following notification
23.	Any additional information	24.	Name of contact and telephone number for queries

Name of authorised official of issuer responsible for making notification: Patrick Huggins, Head of Finance and Company Secretary Date of notification: 19 August 2013

 

END

 

 

RDSLLFVETDIIFIV